Peptomyc raises €1m round from Riva y García

The fresh capital will enable the company to support its preclinical tests and boost its product development. The company expects to enter clinical phase for its cancer treatment drug by 2020.

Healthequity is the PE-dedicated fund of Riva y García and Collegi de Metges de Barcelona. The vehicle specialises in venture capital investments, targeting early-stage business in medical devices, biotech and healthcare services sectors. The fund launched in 2011 with a €15m target.

Company
Established in 2014 and headquartered in Barcelona, Peptomyc develops a protein-based drug targeting cancer treatments.

People
Riva y García – Albert Ferrer Oliveras (investment director).
Peptomyc – Laura Soucek (co-founder, chief scientific officer).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Southern Europe
• Spain